Clinical Trials Browser

Phase 3 × Has announcements × Pemetrexed × Clear all

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT04538664 2026-02-25

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 1 FDA

Uterine Cervical Neoplasms

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3 Active not recruiting

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Phase 3 Completed

376 enrolled 34 charts 1 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03425643 2024-12-03

MK-3475-671

Phase 3 Active not recruiting

797 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02578680 2024-09-20

MK-3475-189

Phase 3 Completed

616 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 2 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02220894 2023-10-10

Keynote 042

Phase 3 Completed

1,274 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02409342 2023-03-15

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3 Completed

572 enrolled 32 charts 2 FDA

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

NCT02367781 2021-08-09

IMpower130

Phase 3 Completed

723 enrolled 28 charts 1 FDA

Carcinoma

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung